
Study Design, Baseline and Open-Label Results from XTEND-CIU: A Phase IV, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Omalizumab through 48 Weeks in Patients with Chronic Idiopathic Urticaria
Casale, Thomas B., Scarupa, Mark D., Holden, Michael, Trzaskoma, Benjamin L., Antonova, Evgeniya, Win, Patrick H.Volume:
139
Langue:
english
Journal:
Journal of Allergy and Clinical Immunology
DOI:
10.1016/j.jaci.2016.12.874
Date:
February, 2017
Fichier:
PDF, 125 KB
english, 2017